Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective

by Dhvani Shah, Maurice Driessen, Nancy Risebrough, Timothy Baker, Ian Naya, Andrew Briggs, Afisi S. Ismaila
Published 2018-05-01

Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a r...

by Peter R. Bremner, Ruby Birk, Noushin Brealey, Afisi S. Ismaila, Chang-Qing Zhu, David A. Lipson
Published 2018-01-01

Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK

by Elisabeth Fenwick, Alan Martin, Melanie Schroeder, Stuart J. Mealing, Oyinkansola Solanke, Nancy Risebrough, Afisi S. Ismaila
Published 2021-03-01

Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial

by Alan Martin, Dhvani Shah, Kerigo Ndirangu, Glenn A. Anley, Gabriel Okorogheye, Melanie Schroeder, Nancy Risebrough, Afisi S. Ismaila
Published 2022-02-01

Characterisation of patients with chronic obstructive pulmonary disease initiating single-device inhaled corticosteroids/long-acting β2-agonist dual therapy in a primary care setti...

by Victoria Banks, Robert Wood, Gema Requena, Alexandrosz Czira, Theo Tritton, Rosie Wild, Chris Compton, Maria Duarte, Afisi S Ismaila
Published 2022-10-01

Preventing clinically important deterioration with single-inhaler triple therapy in COPD

by Ian Naya, Chris Compton, Afisi S. Ismaila, Ruby Birk, Noushin Brealey, Maggie Tabberer, Chang-Qing Zhu, David A. Lipson, Gerard Criner
Published 2018-10-01

Clinical effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol in usual practice: the COPD INTREPID study design

by Sally Worsley, Neil Snowise, David M.G. Halpin, Dawn Midwinter, Afisi S. Ismaila, Elaine Irving, Leah Sansbury, Maggie Tabberer, David Leather, Chris Compton
Published 2019-11-01

Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospe...

by Afisi S. Ismaila, Kieran J. Rothnie, Robert P. Wood, Victoria L. Banks, Lucinda J. Camidge, Alexandrosz Czira, Chris Compton, Raj Sharma, Shannon N. Millard, Olivia Massey, David M. G. Halpin
Published 2023-09-01

Correction: Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation...

by Afisi S. Ismaila, Kieran J. Rothnie, Robert P. Wood, Victoria L. Banks, Lucinda J. Camidge, Alexandrosz Czira, Chris Compton, Raj Sharma, Shannon N. Millard, Olivia Massey, David M. G. Halpin
Published 2024-04-01

The Burden of Illness Related to Chronic Obstructive Pulmonary Disease Exacerbations in Québec, Canada

by Tam Dang-Tan, Shiyuan Zhang, Ruben V. Tavares, Melissa Stutz, Afisi S. Ismaila, Julie Vaillancourt, Diane Corriveau, Richard H. Stanford, Xiwu Lin, Gilbert A. Nadeau, Alexander Simidchiev, Daria Parsons, John S. Sampalis
Published 2017-01-01

INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice

by David M.G. Halpin, Sally Worsley, Afisi S. Ismaila, Kai-Michael Beeh, Dawn Midwinter, Janwillem W.H. Kocks, Elaine Irving, Jose M. Marin, Neil Martin, Maggie Tabberer, Neil G. Snowise, Chris Compton
Published 2021-06-01

Outcomes of patients with COPD switching from multiple-inhaler to once-daily single-inhaler triple therapy in a real-world primary care setting in England: a retrospective pre-post...

by Raj Sharma, Claus F Vogelmeier, Kieran J Rothnie, David M G Halpin, Alexandrosz Czira, Chris Compton, Afisi S Ismaila, Robert P Wood, Victoria L Banks, Lucinda J Camidge, Olivia K I Massey, Monica Seif
Published 2024-03-01